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Abstract 
Epicardial adipose tissue has been proposed to participate in the pathogenesis of heart failure. The 
aim of our study was to assess the expression of thermogenic genes (Uncoupling protein 1 
(UCP1), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), and 
PR-domain-missing 16 (PRDM16) in epicardial adipose tissue in patients with heart failure, 
stablishing the difference according to left ventricular ejection fraction (reduced or preserved). 
Among the 75 patients in our study, 42.7% (n=32) had reduced left ventricular ejection fraction. 
UCP1, PGC1α and PRDM16 mRNA in EAT were significantly lower in patients with reduced left 
ventricular ejection fraction. Multiple regression analysis showed that age, male gender, body max 
index, presence of obesity, type-2-diabetes mellitus, hypertension and coronary artery disease and 
left ventricular ejection fraction were associated with the expression levels of UCP1, PGC1α and 
PRDM16 mRNA. Thermogenic genes expressions in epicardial adipose tissue (UCP1: OR 0.617, 
95%CI 0.103-0.989, p=0.042; PGC1α: OR 0.416, 95%CI 0.171-0.912, p=0.031; PRDM16: OR 
0.643, 95%CI 0.116-0.997, p=0.044) were showed as protective factors against the presence of 
heart failure with reduced left ventricular ejection fraction, and age (OR 1.643, 95%CI 1.001-3.143, 
p=0.026), presence of coronary artery disease (OR 6.743, 95%CI 1.932-15.301, p<0.001) and 
type-2-diabetes mellitus  (OR 4.031, 95%CI 1.099-7.231, p<0.001) were associated as risk factors. 
The adequate expression of thermogenic genes has been shown as possible protective factors 
against heart failure with reduced ejection fraction, suggesting that a loss of functional epicardial 
adipose tissue brown-like features would participate in a deleterious manner on heart metabolism. 
Thermogenic genes could represent a future novel therapeutic target in heart failure. 










Despite improvements in therapy, heart failure 
(HF) remains a leading cause of morbidity and 
mortality, affecting more than 37 million people 
worldwide and conferring a substantial burden on the 
health-care system [1]. It has been demonstrated that 
HF is associated with a pro-inflammatory state, 
mainly through an increase in pro-inflammatory 
adipokines and a decrease in anti-inflammatory adip-
okines, regulated by the expression of thermogenic 
genes [2]. Epicardial Adipose Tissue (EAT) has been 
proposed to participate in this adipokines production 
dysbalance and energy homeostasis, contributing to 
the pathogenesis of HF [3], but has not been fully 
characterized.  
The main aim of our study was to assess the 
expression of thermogenic genes (Uncoupling protein 
1 (UCP1), peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC1α) and PR-domain- 
missing 16 (PRDM16) in EAT in patients with HF, 
stablishing the difference between patients with 
reduced ejection fraction (HFr-EF) and preserved 
ejection fraction (HFp-EF) and to evaluate the 
association with clinical and biochemical variables. 
Material and Methods  
Patients 
Patients with HF who underwent elective 
cardiac surgery (coronary artery bypass and/or valve 
replacement) were included in our study and divided 
according to left ventricular ejection fraction (LVEF) 
determined by left ventriculography. HFr-EF was 
defined as an EF ≤40%, whereas HFp-EF was defined 
as an EF >40%. Exclusion criteria were severe infe-
ctions, acute inflammatory diseases and/or cancer. 
Data about demographics and clinical characteristics, 
and biochemical parameters were collected.  
The study was approved by the Institutional 
Research Ethics Committee from Hospital 
Universitario Virgen de la Victoria (Málaga, Spain) 
and carried out in accordance with the Declaration of 
Helsinki. Only patients who had previously given 
written informed consent were enrolled in this study. 
Biological material  
EAT biopsy samples (0.2-0.5g) were obtained 
near the proximal right coronary artery 1 hour after 
anesthesia. All the tissues were immediately frozen in 
liquid nitrogen and stored at -80ºC for RNA isolation.  
In addition, peripheral venous blood was 
obtained and drawn into pyrogen-free tubes with or 
without ethylenedianminetetraacetic acid (anticoag-
ulant). For serum, the tubes were left at room 
temperature for 20 min and then centrifuged at 1500 g 
for 10 min at 4ºC. In the hospital laboratory, fasting 
glucose, glycated hemoglobin (HbA1c), total 
cholesterol, low-density lipoprotein (LDL), 
high-density lipoprotein (HDL), triglycerides, 
creatinine, uric acid, glutamic-oxolacetic transaminase 
(GOT), glutamate-piruvate transaminase (GPT), 
gamma-glutamyl transferase (GGT), C-reactive 
protein (CRP), calcium, sodium and potassium were 
measured in a Dimension autoanalyzer (Dade 
Behring Inc., Deerfield, IL) by enzymatic methods 
(Randox Laboratories, Ldt., UK).  
The gene expression levels in the adipose tissue 
were determined by real time quantitative 
polymerase chain reaction (PCR) using a predesigned 
and validated Taqman primer/probe sets. 
Statistical analysis 
Continuous variables are summarized as mean ± 
standard deviation with Student’s T test used to test 
the significance of between-group differences. 
Discrete variables are presented as frequencies and 
percentages with between-group differences tested 
using Pearson chi-square test. Multiple regression 
analysis were used in order to identify independent 
predictors of EAT UCP1, PGC1α and PRDM16 levels, 
as well as to control for confounding factors; and 
those clinical variables that achieved P<0.05 on 
between-group comparison and cardiovascular 
plausible variables were included in the model. 
Logistic regression analysis was used to define the 
risk factors of reduced LVEF, and odds ratio (OR) and 
95% Confidence Interval (95%CI) were calculated. 
SPSS for Windows version 15 (SPSS Inc. Chicago, IL, 
USA) was used for analyses and values were 
considered significant at P<0.05. 
Results  
Among the 75 patients in our study, 42.7% 
(n=32) had reduced LVEF. Clinical and laboratory 
differences between patients with reduced and 
preserved LVEF HF are listed in Table 1. Among 
patients with reduced LVEF, there were more men 
and more likely to have coronary artery disease and 
obesity, and less valve heart disease. 
UCP1, PGC1α and PRDM16 mRNA in EAT were 
significantly lower in patients with reduced LVEF 
(P=0.004, P=0.002 and P=0.02, respectively) (Figure 1). 
Multiple regression analysis showed that age, 
male gender, body max index (BMI), presence of 
obesity, type-2-diabetes mellitus (DM2), hypertension 
and coronary artery disease and LVEF were 




independently associated with EAT UCP1, PGC1α, 
and PRDM16 mRNA levels (Table 2).  
Thermogenic genes expressions in EAT were 
showed as protective factors against the presence of 
HFr-EF, and age, presence of coronary artery disease 
and type-2-diabetes mellitus were associated as risk 
factor in the logistic regression analysis (Table 3).  
 
Table 1. Clinical and laboratory characteristics of patients with 









Age, years 62.5 ± 10.3 62.8 ± 11.5 0.718 
Male gender 26 (81.3) 28 (65.1) 0.003 
Body mass index, kg/m2 26.6 ± 4.4 29.4 ± 5.3 0.03 
LVEF, % 34.9 ± 3.9 60.4 ± 8.5 <0.001 
Cardiovascular risk factors 
Current smoking 14 (43.8) 16 (37.2) 0.267 
Dyslipidemia 15 (46.9) 23(53.5) 0.317 
Hypertension 17 (53.1) 25 (58.1) 0.296 
Diabetes mellitus 10 (31.3) 16 (37.2) 0.277 
Obesity 14 (43.8) 21 (48.8) 0.127 
Coronary artery disease 19 (59.4) 17 (39.5) 0.04 
Multivessel coronary disease 22 (68.8) 30 (69.8) 0.431 
Valve heart disease 15 (46.9) 28 (65.1) 0.03 
Cerebrovascular disease 3 (9.4) 3 (7) 0.442 
Medications 
Aspirin 17 (53.1) 24 (55.8) 0.766 
Statin 14 (43.8) 22 (51.2) 0.104 
ACEI/ARB 19 (59.4) 25 (58.1) 0.425 
Beta-blocker 21 (65.6) 31 (72.1) 0.370 
Biochemical data 
Glucose, mg/dL 129.8 ± 57.7 122.1 ± 43.7 0.349 
HbA1c, % 6.6 ± 1.3 6.2 ± 1.3 0.721 
Total cholesterol, mg/dL 160± 36 163± 42 0.395 
LDL cholesterol, mg/dL 97± 39 98± 33 0.381 
HDL cholesterol, mg/dL 40± 8.5 39 ± 14 0.320 
Triglycerides, mg/dL 161± 53 144± 61 0.197 
Creatinine, mg/dL 1.3± 0.8 1 ± 0.4 0.711 
Uric acid, mg/dL 6.7± 3.6 5.6± 1.9 0.07 
GOT, IU/L 28.9± 11.9 35.3 ± 37 0.112 
GPT, IU/L 33.9± 18.9 36.9± 29.1 0.426 
GGT, IU/L 61.6± 44.8 52.1± 57.6 0.479 
CRP, mg/dL 27.1± 46.6 17± 32.9 0.222 
Calcium, mg/dL 8.5 ± 0.7 8.5± 0.8 0.858 
Potassium, mmol/L 4.2± 0.7 4.3± 0.4 0.855 
Sodium, mmol/L 136± 4.4 138± 3.5 0.342 
Values are shown as mean ± standard deviation and frequencies (percentages).  
Values were considered to be statistically significant when P<0.05. 
ACEI: Angiotensin Converting Enzyme Inhibitor; ARB: Antiotensin II Receptro 
Blocker; CRP: C-Reactive Protein; GGT: Gamma-Glutamyl Transferase; GOT: 
Glutamic-Oxolacetic Transaminase; GPT: Glutamate-Piruvate Transaminase; 
Hb1ac: glycated hemoglobin; HDL: High-Density Lipoprotein; HFp-EF: heart 
failure with preserved ejection fraction; HFr-EF: heart failure with reduce ejection 
fraction; IU/L: international units/liter; kg/m2: kilogram/square metre; LDL: 




The present study found that patients with 
HFr-EF expressed significantly lower thermogenic 
genes (UCP1, PGC1α and PRDM16) in EAT than 
those with HFpEF. Age, male gender and different 
cardiovascular diseases were associated with the 
levels of thermogenic genes expression. EAT UCP1, 
PGC1α and PRDM16 mRNA levels were shown as 
possible protective factors against HFr-EF, and age 





Figure 1. UCP1 (A), PGC1α(B) and PRDM16 (C) mRNA expression in EAT 
comparison between groups. Values are shown as mean ± standard deviation. Values 
were considered to be statistically significant when P<0.05. EAT: epicardial adipose 
tissue; HFp-EF: heart failure preserved-ejection fraction; HFr-EF: heart failure reduced 
ejection fraction; PGC1α: peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha; PRDM16: PR-domain-missing 16; UCP1: uncoupling protein 1  





Table 2. Multiple regression analysis for prediction of epicardial adipose tissue UCP1, PGC1α and PRDM16 mRNA levels 
Variables EAT UCP1 mRNA (R2=0.503) EAT PGC1α mRNA (R2=0.641) EAT PRDM16 mRNA (R2=0.499) 
β 95%CI P value β 95%CI P value β 95%CI P value 
Age 0.071 0.019-0.132 0.032 0.099 0.032-0.199 0.003 0.079 0.041-0.177 0.041 
Gender (Man) 0.119 -0.043-(-0.291) 0.040 -0.152 -0.064-(-0.237) 0.001 -0.101 -0.041-(-0.301) 0.041 
Body mass index -0.090 -0.002-(-0.301) 0.041 -0.181 -0.001-(-0.248) 0.039 -0.088 -0.012-(-0.431) 0.049 
Obesity -0.281 -0.108-(-0.931) 0.029 -0.381 -0.119-(-0.849) 0.022 -0.229 -0.099-(-0.983) 0.041 
Diabetes Mellitus -0.230 -0.101-(-0.931) 0.041 -0.460 -0.159-(-0.869) 0.044 -0.201 -0.032-(-0.899) 0.044 
Hypertension  0.083 0.021-0.333 0.044 0.131 0.021-0.343 0.039 0.072 0.012-0.435 0.049 
Dyslipidemia 0.145 -0.241-2.001 0.519 0.243 -0.343-1.141 0.439 0.198 -0.341-1.191 0.321 
Coronary artery Disease -0.111 -0.003-(-0.801) 0.041 -0.098 -0.003-(-0.798) 0.038 -0.131 -0.003-(-0.813) 0.044 
LVEF 0.222 0.081-0.344 0.002 0.399 0.049-0.598 0.001 0.119 0.052-0.301 0.002 
Values were considered to be statistically significant when P < 0.05 
CI: Confidence Interval; EAT: epicardial adipose tissue; LVEF: left ventricular ejection fraction; PGC1α: peroxisome proliferator-activated receptor gamma coactivator 
1-alpha; PRDM16: PR-domain-missing 16; UCP1: uncoupling protein 1. 
 
 
Table 3. Logistic regression analysis for the presence of heart 
failure with reduced ejection fraction 
Variable OR (95% CI) P value 
UCP1 mRNA 0.617 (0.103-0.989) 0.042 
PGC1α mRNA 0.416 (0.171-0.912) 0.031 
PRMD16 mRNA 0.643 (0.116-0.997) 0.044 
Age 1.643 (1.001-3.143) 0.026 
Gender (man) 7.867 (0.717-26.101) 0.223 
Body mass index 2.341 (0.683-8.033) 0.312 
Obesity 3.001 (0.843-12.301) 0.323 
Diabetes mellitus 4.031 (1.099-7.231) <0.001 
Hypertension 2.499 (0.798-14.133) 0.492 
Dyslipidemia 3.301 (0.639-9.103) 0.329 
Coronary artery disease 6.743 (1.932-15.301) <0.001 
Values were considered to be statistically significant when P<0.05. 
CI: confidence Interval; OR: odds ratio; PGC1α: peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha; PRDM16: PR-domain-missing 16; UCP1: 
uncoupling protein 1. 
 
 
These findings are important because they 
support the hypothesis that EAT thermogenic 
function could play an important role in the 
pathogenesis of HF. This is one of very few studies 
that have explored the influence of EAT on heart 
function in patients with HF and this is unique in that 
it assessed the association between thermogenic genes 
expression and HFr-EF and HFp-EF.   
EAT represents a visceral brown-like adipose 
tissue located between the myocardium and the inner 
layer of visceral pericardium with a close anatomical 
proximity to the myocardium [4]. A functional EAT 
has been proposed to play a protector role over the 
myocardium but in pathological situations may be 
implicated in the development and/or progression of 
heart disease [3-5]. Several studies have shown that 
EAT is associated with the pathogenesis of HF, but 
focusing on EAT volume determined by 
echocardiography, magnetic resonance or computed 
tomography. Increased EAT thickness has been 
related to the severity of HF and explored the 
influence on diastolic and systolic functions [6,7]. 
However, only limited studies have explored the 
functionality of EAT [2,8]. Recent investigations have 
assessed the relationship between EAT gene 
expression in patients with HF, finding a functional 
role of EAT in the regulation of the development of 
HF [8]. p53, a tumor suppressor that coordinates DNA 
repair, cell cycle arrest and apoptosis; and 
adiponectin, an important anti-inflammatory 
adipokine, have been the principal gene expressions 
suggested to be important mediators of HF 
progression [9].  
A number of reports have investigated the 
association between thermogenic gene expression 
such as UCP1, PGC1α and PRDM16, and coronary 
artery disease and other cardiovascular risk factors 
[10]. These genes have been recognized as specific 
marker of brown adipocites and regulators of 
oxidative metabolism and mitochondrial biogenesis, 
playing a relevant role in cardiac status [2]. A decrease 
of their gene mRNA expressions in EAT in patients 
with HFr-EF suggests a loss of EAT brown-like 
features, promoting pro-inflammatory and 
atherosclerotic pathways, exposing the heart to an 
excessive toxicity [11]. In line with these finding, we 
showed the thermogenic function of EAT and its 
involvement in the LVEF.   
We acknowledge the following limitations in this 
study. We recruited a small number of recruited 
patients; our data were from a single hospital; and 
only small EAT biopsy samples were taken, being 
insufficient for a proteins determination. However, 
our study was carried out using a well-designed 
protocol and well-stablished methods. The hypothesis 
that EAT thermogenic genes expression was involved 
in patients with HF and influenced according to LVEF 
would need to be confirmed in a larger and 
multicenter research study.  
In conclusion, the expression of thermogenic 
genes (UCP1, PGC1α and PRDM16) was lower in 
patients with HFr-EF than in those with HFp-EF. 
These genes have been shown as possible protective 
factors against HFr-EF, suggesting a loss of functional 
EAT brown-like features, what, subsequently, would 
participate in a deleterious manner on heart 




metabolism. Thermogenic genes could represent a 
future novel therapeutic target in patients with 
HFr-EF.    
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